Abstract RTS, S/AS01 (Mosquirix®) is a vaccine against malaria caused by Plasmodium
falciparum. In a phase 3 trial, RTS, S/AS01 showed vaccine efficacy against clinical malaria …

Malaria is an illness caused by Plasmodium parasites transmitted to humans by infected
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …

Objective: To summarize and evaluate the literature for Mosquirix (RTS, S) and provide
insight into the therapeutic and economic controversies of this novel malaria vaccine …

Malaria is a parasitic infection caused by bites from Plasmodium falciparum (P. falciparum)-
infected mosquitoes with a present scale of symptoms ranging from moderate fever to …

Background The RTS, S/AS02D vaccine has been shown to have a promising safety profile,
to be immunogenic and to confer protection against malaria in children and infants. Methods …

A workshop on implementation strategies for the introduction of the RTS, S/AS01 (RTS, S)
malaria vaccine in countries with areas of highly seasonal transmission, was held as a …

Background The development of a malaria vaccine remains a public health priority for sub‐
Saharan Africa. RTS, S/AS02A candidate malaria vaccine has been shown to be safe and …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Background Following a 30-year development process, RTS, S/AS01E (GSK, Belgium) is
the first malaria vaccine to reach Phase IV assessments. The World Health Organization …

The first clinical Phase III trial evaluating a malaria vaccine was completed in December
2013 at 11 sites from seven sub-Saharan African countries. This systematic review assesses …